TROPION-Breast02

NCT05374512 📎

Regimen

Experimental
Datopotamab deruxtecan-dlnk 6 mg/kg IV Q3W.
Control
Investigator's choice single-agent chemotherapy (paclitaxel, nab-paclitaxel, carboplatin, capecitabine, or eribulin).

Population

Previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer, not candidates for PD-(L)1 inhibitors (PD-L1 low/negative, or contraindication).

Key finding

TROPION-Breast02 demonstrated datopotamab deruxtecan superior to chemotherapy in IO-ineligible 1L metastatic TNBC. Basis for NCCN v2.2026 listing of datopotamab as a preferred recommendation in first line.

Timeline

    Guideline citations

    • NCCN BREAST